





S2 Fig. The association between circulating tumor DNA (ctDNA) status and clinical features. (A) The overview of the patients according to the ctDNA status and clinicopathological features. (B) The proportion of patients with detectable ctDNA and with undetectable ctDNA according to clinicopathological features. PSA, prostate specific antigen.